Related Experiment Videos
Modulation of spontaneous B-cell differentiation in macroglobulinemia by retinoic acid
Y Levy1, S Labaume, M C Gendron
1Laboratory of Immunopathology, Hôpital Saint-Louis, Paris, France.
Abstract:
We previously showed that clonal blood B cells from patients with macroglobulinemia spontaneously differentiate in vitro to plasma cells. This process is dependent on an interleukin (IL)-6 autocrine pathway. We investigate here whether all-trans-retinoic acid (RA) interferes with B-cell differentiation either in patients with IgM gammapathy of undetermined significance (MGUS) or Waldenström's macroglobulinemia (WM). RA at a concentration of 10(-5) to 10(-8) mol/L inhibited by 50% to 80% the in vitro differentiation of purified B cells from four of five patients with MGUS and from one of five patients with WM as assessed by the IgM content of day 7 culture supernatants. We next determined whether this effect could be related to an inhibition of IL-6 secretion by cultured B cells and/or a downregulation of the IL-6 receptor (IL-6R), which was constitutively expressed on patients' blood B cells. A 50% to 100% (mean, 80%) inhibition of IL-6 production was found in seven of 10 patients (five with MGUS and two with WM). The IL-6R was no more detectable on cells from patients with MGUS after 2 days of treatment with RA and slightly downregulated in patients with WM. It was of interest that B cells susceptible to the action of RA belonged mostly to patients with IgM MGUS, which reinforces our previous data showing distinct requirements for IL-6-dependent differentiation of blood B cells from patients with VM or IgM MGUS.
Insights
All-trans-retinoic acid (RA) inhibits B-cell differentiation in patients with IgM monoclonal gammopathy of undetermined significance (MGUS) and Waldenström's macroglobulinemia (WM). RA reduces interleukin-6 (IL-6) production and IL-6 receptor expression, impacting B-cell to plasma cell maturation.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Clonal B cells in macroglobulinemia spontaneously differentiate into plasma cells via an interleukin-6 (IL-6) autocrine pathway.
- Understanding factors influencing B-cell differentiation is crucial for managing lymphoproliferative disorders.
Purpose of the Study:
- To investigate the effect of all-trans-retinoic acid (RA) on B-cell differentiation in patients with IgM monoclonal gammopathy of undetermined significance (MGUS) and Waldenström's macroglobulinemia (WM).
- To determine if RA interferes with IL-6 secretion or IL-6 receptor (IL-6R) expression in these patient populations.
Main Methods:
- Purified B cells from MGUS and WM patients were cultured in vitro with varying concentrations of RA.
- B-cell differentiation was assessed by measuring IgM content in culture supernatants.
- IL-6 production and IL-6R expression on B cells were analyzed following RA treatment.
Main Results:
- RA significantly inhibited in vitro B-cell differentiation in 50-80% of MGUS patients and 20% of WM patients.
- RA treatment led to a mean 80% inhibition of IL-6 production in responsive patients.
- RA treatment downregulated IL-6R expression on B cells from MGUS and WM patients.
Conclusions:
- All-trans-retinoic acid demonstrates potential as an agent to modulate aberrant B-cell differentiation in IgM MGUS and WM.
- The mechanism involves the suppression of IL-6 production and downregulation of IL-6R, disrupting the autocrine IL-6 pathway.
- B cells from IgM MGUS patients appear more susceptible to RA's inhibitory effects, suggesting distinct pathway requirements compared to WM.